Skip to main content
. 2012 May 5;71(11):1872–1880. doi: 10.1136/annrheumdis-2011-201180

Figure 5.

Figure 5

SuperAnxA1 accelerates resolution of K/BxN arthritis. AnxA1+/+ mice (n=6) were given an intraperitoneal injection of K/BxN serum (50 μl at day 0 and day 2) and then received vehicle, human recombinant AnxA1 or SuperAnxA1 (1 µg intraperitoneally daily from day 2). (A) PR3 gene product expression was analysed with Ct values normalised to endogenous Gapdh. RQ values were calculated using 2−(ΔΔCt) and data shown here as mean±SE. Naive mice (D0) were set as the calibrator samples. *p<0.05 versus naive (Student t test). (B) Arthritic score. *p<0.05 versus vehicle control (two-way analysis of variance). (C) Right ankles of mice from each experimental group were taken at day 10 and joints processed for staining by H&E and safraninO. Representative images are shown. Scale bars, 50 μm. CE, cartilage erosion; PF, pannus formation; S, synovitis. (D) Histomorphometric analyses of joint sections. *p<0.05 versus vehicle control (Student t test).